| Fiscal Year End | Company Status | Exempt Flag |
| September 30 | Trading | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 4/Mar/1983 | | Canada | | |
|
|
| Exchange Filing Office |
| Location |
| Toronto Regional Service Office |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| Research and Development of Pharmaceutical Products
| "Arch Biopartners is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's lead drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the leading cause of kidney failure worldwide."
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| ARCH | Arch Biopartners Inc. | TSX Venture | TRADING |
|
|
| Name History | From | To |
| Arch Biopartners Inc. | 15/Apr/2014 | Present |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
